icd 10 code for xanthelasma

Imagine looking in the mirror and noticing soft, yellowish patches slowly emerging on your eyelids. They are painless, they do not itch, and they grow so gradually that you might not even notice them at first. For millions of individuals worldwide, this is the reality of xanthelasma palpebrarum, the most common form of cutaneous xanthoma. While often dismissed as a mere cosmetic blemish, these seemingly innocuous plaques are, in fact, a profound dermatological window into the body’s internal metabolic state. They are the physical manifestation of lipid-laden macrophages—immune cells that have gorged themselves on cholesterol—nestling within the dermis of the eyelids. Their presence whispers a question, sometimes a shout, about underlying systemic health, most notably dyslipidemia, a condition characterized by abnormal levels of fats in the blood. This article delves deep into the world of xanthelasma, moving beyond the surface to explore its clinical nuances, its precise classification in the modern medical coding system (ICD-10), its intimate connection with cardiovascular health, and the full spectrum of management strategies available to patients and clinicians. Understanding xanthelasma is not just about erasing a mark; it’s about interpreting a sign and potentially preventing a future cardiovascular event.

2. Clinical Presentation: What Does Xanthelasma Look Like?

Xanthelasma palpebrarum presents as distinctive, well-demarcated, yellowish-to-orange papules or plaques. They are typically located on the periorbital skin, with a strong predilection for the medial aspects of the upper eyelids, though the lower eyelids can also be involved. The lesions are soft in consistency, non-tender, and their size can vary dramatically from tiny, pinhead-sized papules to large, confluent plaques that can cover a significant portion of the eyelid. Their growth is characteristically indolent, progressing slowly over months or even years. The surface can be smooth or have a velvety texture, and the borders are often irregular but clearly defined from the surrounding normal skin.

• Symmetry: While they can be unilateral, bilateral and symmetrical presentation is far more common, which often reinforces the diagnosis.

• Sensation: They are almost invariably asymptomatic, causing no pain, pruritus (itching), or discomfort. The primary patient concern is almost always aesthetic, though larger lesions can, in rare cases, cause mechanical ptosis (drooping of the eyelid).

• Distribution: The medial canthus (the inner corner of the eye) is the epicenter, but lesions can extend laterally along the eyelid folds.

[Image: A high-quality clinical photograph showing classic, bilateral, symmetrical xanthelasma plaques on the upper and lower eyelids of a patient.]

3. The Crucial ICD-10 Code: H02.69 and Its Proper Application

In the realm of medical administration, insurance billing, and epidemiological tracking, precise coding is paramount. The International Classification of Diseases, Tenth Revision (ICD-10) provides a standardized system for this purpose. For xanthelasma palpebrarum, the correct code is H02.69.

It is essential to break down this code to understand its specificity and avoid common coding errors:

• Chapter: H00-H59 – This chapter encompasses “Diseases of the eye and adnexa.” The adnexa refer to accessory structures, which include the eyelids, eyebrows, conjunctiva, and lacrimal apparatus.

• Block: H02 – This block is dedicated specifically to “Disorders of eyelid, lacrimal system and orbit.”

• Category: H02.6 – This category covers “Other degenerative disorders of eyelid and periocular area.”

• Code: H02.69 – This is the final, specific code for “Other degenerative disorders of eyelid and periocular area.” Within the ICD-10 index, looking up “Xanthelasma” directs you to “see Xanthelasma, eyelid,” which in turn directs you to code H02.69.

Why is this code correct? Xanthelasma is classified as a degenerative disorder because it involves the accumulation of a substance (lipid) within the skin tissue, leading to a change in its structure and function. It is crucial to note that this code is used regardless of whether the xanthelasma is associated with an underlying lipid disorder. The code describes the physical lesion itself.

Common Coding Pitfalls to Avoid:

• Do not use codes for hyperlipidemia (E78.0-E78.5) as the primary code for the xanthelasma lesion. These codes are for the systemic metabolic condition, not the localized skin manifestation. A patient may have both codes, but if the encounter is for the treatment or diagnosis of the eyelid lesion, H02.69 is primary.

• Do not use unspecified codes when a specific code exists. Using H02.9 (Unspecified disorder of eyelid) would be inaccurate and could lead to claim denials or poor data quality.

 ICD-10 Coding Scenarios for Xanthelasma

4. Epidemiology: Who is Affected?

Xanthelasma is the most prevalent type of xanthoma, with an estimated incidence in the general population ranging from 0.3% to 1.5%. Its occurrence is not uniform across all demographics. It demonstrates a distinct predilection for middle-aged and elderly individuals, with the peak incidence occurring between the ages of 40 and 60. However, cases in younger adults and even children (typically associated with familial hypercholesterolemia) have been documented.

A notable and consistent epidemiological finding is a higher prevalence in females compared to males. The reasons for this gender disparity are not entirely clear but may be related to hormonal influences or differences in healthcare-seeking behavior for cosmetic concerns. There is no well-established racial or geographic predilection for xanthelasma, as it occurs across all ethnic groups worldwide, reflecting its fundamental link with lipid metabolism, which is a universal human biological process.

5. Pathophysiology: The Biological Mechanism Behind the Lesions

To understand xanthelasma is to understand the journey and fate of lipids in the skin. The pathophysiology is a captivating process that bridges systemic metabolism and local tissue response.

Step 1: The Systemic Dyslipidemia
The story often begins with an abnormality in the blood lipid profile. The key players are:

• Low-Density Lipoprotein (LDL) Cholesterol: Often termed “bad cholesterol,” elevated levels of LDL are the most significant contributor. LDL particles are rich in cholesterol and are designed to deliver it to peripheral tissues.

• Lipoprotein(a) [Lp(a)]: This is a genetic variant of LDL that has an additional protein attached. High levels of Lp(a) are an independent, strong risk factor for atherosclerosis and are also highly associated with xanthelasma.

• Apolipoproteins: Dysregulation in apolipoproteins, the protein components that structure lipoproteins (e.g., ApoB100 on LDL), can also play a role.

In many patients with xanthelasma, the levels of these atherogenic particles are elevated in the bloodstream. However, it is critical to note that a substantial proportion (up to 50%) of patients with xanthelasma have normal serum lipid levels. This suggests that local tissue factors are equally important.

Step 2: Vascular Permeability and LDL Trapping
The dermal capillaries are the conduits through which blood, including lipoproteins, flows. In the periorbital region, which has a rich vascular network, increased capillary permeability can allow LDL particles to extravasate—that is, to leak out of the bloodstream and into the surrounding dermal tissue.

Step 3: Oxidation and the Inflammatory Cascade
Once trapped in the dermis, the LDL particles undergo a critical modification: oxidation. Oxidized LDL (oxLDL) is no longer a simple nutrient carrier; it becomes a potent pro-inflammatory signal. It acts as a “danger signal,” activating the local endothelial cells and attracting monocytes, a type of white blood cell, from the circulation.

Step 4: Foam Cell Formation – The Birth of a Xanthelasma
The monocytes that migrate into the dermis differentiate into macrophages. Their normal role is to engulf and digest pathogens or debris. They recognize and avidly engulf the oxidized LDL particles via specific scavenger receptors. However, these macrophages lack an effective “off-switch” for this ingestion process. They continue to consume oxLDL until their cytoplasm becomes so engorged with lipid droplets—primarily cholesterol esters—that they take on a characteristic foamy, bubbly appearance under the microscope. These are now called foam cells (xanthoma cells).

Step 5: Nodule and Plaque Formation
The accumulation of countless foam cells in the superficial and mid-dermis forms the bulk of the xanthelasma lesion. These cells cluster together, expanding the dermal tissue and creating the visible yellowish plaque. There is typically a surrounding mild chronic inflammatory infiltrate with T-lymphocytes, highlighting the ongoing immune response. The overlying epidermis is often normal but can be stretched thin or slightly acanthotic (thickened).

[Image: A detailed histopathology slide showing the dermis packed with foam cells, which have a bubbly cytoplasm, characteristic of a xanthelasma. The overlying epidermis is normal.]

6. The Critical Link to Systemic Health: Dyslipidemia and Beyond

The presence of xanthelasma is a red flag that should prompt a thorough systemic evaluation. It is a cutaneous sentinel for internal metabolic disturbances.

A. Dyslipidemias:
This is the most robust association. Patients with xanthelasma have a significantly higher prevalence of:

• Type IIa Hyperlipoproteinemia (Familial Hypercholesterolemia): Characterized by very high LDL cholesterol levels, tendon xanthomas, and a high risk of premature cardiovascular disease.

• Type IIb Hyperlipoproteinemia: Elevated LDL and triglycerides.

• Dyslipidemia with elevated Lp(a): As mentioned, Lp(a) is a major independent risk factor.
  Even in normolipidemic patients (those with normal cholesterol levels), more subtle abnormalities in lipoprotein composition and function may be present.

B. Cardiovascular Disease Risk:
Landmark epidemiological studies, such as the Copenhagen City Heart Study, have provided compelling evidence. This large prospective study found that individuals with xanthelasma had a significantly increased risk of ischemic heart disease, myocardial infarction, and severe atherosclerosis, even after adjusting for traditional risk factors like plasma cholesterol, BMI, and smoking. For women, the increased risk was particularly pronounced. This suggests that xanthelasma is not just a marker of high cholesterol but an independent indicator of an underlying atherosclerotic process. The same pathophysiological mechanisms—LDL oxidation, foam cell formation, and inflammation—are occurring in the coronary arteries and the eyelid skin simultaneously.

C. Other Associated Conditions:
While less common, xanthelasma can also be associated with:

• Primary Biliary Cholangitis: An autoimmune liver disease that causes profound hypercholesterolemia.

• Hypothyroidism: Can cause secondary dyslipidemia.

• Diabetes Mellitus: Often associated with a dyslipidemic profile (high triglycerides, low HDL).

• Nephrotic Syndrome: Renal protein loss leads to compensatory hepatic lipoprotein overproduction.

7. Differential Diagnosis: Conditions That Mimic Xanthelasma

A skilled clinician must distinguish xanthelasma from other conditions that can cause yellowish lesions on the eyelids.

1. Syringoma: These are benign tumors of the eccrine sweat ducts. They present as small, skin-colored or yellowish-brown, firm papules, typically on the lower eyelids. They are often mistaken for xanthelasma but are usually more solid and less “waxy” in appearance.

2. Milia: These are tiny, superficial epidermal cysts filled with keratin. They appear as white or yellowish, firm, 1-2 mm papules. They are easily distinguished by their small size and discrete, cystic nature.

3. Sebaceous Hyperplasia: This involves benign enlargement of sebaceous glands. They present as soft, yellowish papules with a central umbilication (dell). They are common on the face, including the eyelids.

4. Juvenile Xanthogranuloma: A benign histiocytic disorder that typically presents in children as reddish-orange to yellow papules or nodules. It is histologically distinct from xanthelasma.

5. Necrobiotic Xanthogranuloma: A rare, severe condition associated with paraproteinemia. The lesions are more indurated, have a violaceous (purplish) border, and can ulcerate, unlike the stable plaques of xanthelasma.

A definitive diagnosis is usually made clinically, but in ambiguous cases, a skin biopsy will provide a histopathological confirmation.

8. Diagnostic Workup: From Clinical Examination to Laboratory Tests

The evaluation of a patient with xanthelasma is twofold: confirming the diagnosis of the lesion and screening for underlying systemic disorders.

1. Clinical Diagnosis:

• History: Inquire about the duration and progression of the lesions, any personal or family history of high cholesterol, heart disease, stroke, diabetes, or thyroid/liver disease.

• Physical Examination: A thorough skin examination to confirm the classic appearance and distribution of xanthelasma. The clinician should also look for other types of xanthomas (e.g., tuberous, tendon) in other locations, which would strongly suggest a significant underlying dyslipidemia. A general physical exam should include checking for signs of arcus cornealis (a white ring around the iris), which is another corneal sign of hyperlipidemia.

2. Laboratory Investigations:
A fasting lipid panel is the cornerstone of the laboratory workup. This should include:

• Total Cholesterol

• LDL Cholesterol (calculated or direct)

• HDL Cholesterol

• Triglycerides
  Based on clinical suspicion, further testing may be warranted:

• Lipoprotein(a) [Lp(a)]: Highly recommended given its strong association.

• Liver Function Tests (LFTs): To rule out primary biliary cholangitis or other liver diseases.

• Thyroid-Stimulating Hormone (TSH): To screen for hypothyroidism.

• Fasting Blood Glucose or HbA1c: To screen for diabetes.

• Renal Function Tests and Urinalysis: If nephrotic syndrome is suspected.

9. Treatment Modalities: Eradicating the Lesions

The decision to treat xanthelasma is primarily driven by cosmetic concerns, though occasionally by functional impairment. It is imperative to counsel the patient that treatment of the lesion does not address the potential underlying systemic risk, which must be managed separately. All treatment modalities carry a risk of recurrence, as they address the symptom (the foam cells) but not the root cause (the dyslipidemia).

9.1. Medical Management

• Topical Agents: Options like trichloroacetic acid (TCA) peels can be applied in-clinic. TCA causes chemical destruction and coagulation of the tissue, leading to sloughing off of the lesion. It is best for very superficial, small plaques. Concentrations must be carefully controlled to avoid scarring or pigmentary changes.

• Systemic Lipid-Lowering Agents: While statins (e.g., atorvastatin, rosuvastatin) are the first-line treatment for the underlying dyslipidemia, their direct effect on existing xanthelasma is variable. Some studies show regression or stabilization of lesions with aggressive lipid-lowering therapy, while others show minimal change. The primary goal of these medications is to reduce cardiovascular risk, not to treat the skin lesions.

9.2. Surgical Excision
This is a classic and highly effective method, especially for well-defined, larger lesions.

• Procedure: The lesion is surgically excised under local anesthesia, and the wound is closed with fine sutures.

• Advantages: Provides a tissue sample for histopathological confirmation. High success rate in a single session.

• Disadvantages: Invasive, requires local anesthesia, risk of scarring, ectropion (out-turning of the eyelid) or entropion (in-turning) if too much skin is removed, and potential for wound dehiscence.

9.3. Ablative and Non-Ablative Laser Therapy
Laser treatment has become a gold standard due to its precision and excellent cosmetic outcomes.

• Ablative Lasers (CO2, Er:YAG): These lasers vaporize water-containing tissue, effectively ablating the xanthelasma layer by layer with extreme precision. They offer excellent hemostasis (control of bleeding) and allow the physician to sculpt the lesion away until the normal dermal plane is reached.

• Non-Ablative/Vascular Lasers (Pulsed Dye Laser – PDL): PDL targets oxyhemoglobin in the blood vessels that feed the xanthelasma. By destroying the microvasculature, it indirectly starves the foam cells of nutrients, leading to lesion regression. It is less effective for thick plaques but has a lower risk of scarring and pigmentary changes.

9.4. Chemical Cauterization and Cryotherapy

• Cryotherapy: Liquid nitrogen is applied to freeze and destroy the cells. It is quick and inexpensive but can be difficult to control the depth of destruction, leading to hypopigmentation (lightening of the skin) or incomplete treatment.

• Electrodessication and Curettage: The lesion is scraped off (curettage) after being desiccated with an electrocautery device. It is a good option for pedunculated or soft lesions.

The choice of treatment is a shared decision between the patient and the physician, based on the size, location, and depth of the lesion, the clinician’s expertise, available resources, and the patient’s preference and risk tolerance.

[Image: A series of three photos showing a xanthelasma before treatment, immediately after CO2 laser ablation, and several weeks post-treatment showing excellent healing with minimal scarring.]

10. Prognosis, Recurrence, and Long-Term Management

The prognosis for the xanthelasma lesions themselves is generally good in terms of treatability, but the risk of recurrence is high, reported in 40-60% of cases within 5 years, regardless of the treatment modality used. Recurrence can occur at the same site or in adjacent periorbital skin. This high recurrence rate underscores the fact that the local treatment does not alter the systemic metabolic milieu that gave rise to the lesions in the first place.

Therefore, the long-term management of a patient with xanthelasma must be holistic:

1. Aggressive Management of Dyslipidemia: This is the cornerstone. Achieving target LDL-C and Lp(a) levels through lifestyle modifications (heart-healthy diet, regular exercise, smoking cessation) and pharmacotherapy (statins, ezetimibe, PCSK9 inhibitors) is paramount.

2. Regular Follow-up: Patients should have regular follow-ups with their primary care physician or cardiologist for monitoring of their lipid profile and overall cardiovascular risk.

3. Realistic Expectations for Lesion Treatment: Patients should be counseled that while the visible lesion can be successfully removed, it may come back, and the primary focus of care is on their internal health to prevent heart attacks and strokes.

11. Conclusion

Xanthelasma palpebrarum, coded as ICD-10 H02.69, is far more than a cosmetic curiosity. It is a complex dermatological condition born from the interplay of systemic dyslipidemia and local dermal factors, resulting in the characteristic accumulation of lipid-laden foam cells. Its presence serves as a critical, visible clue to underlying metabolic disturbances and a significantly elevated risk of cardiovascular disease. A comprehensive approach—encompassing accurate diagnosis, appropriate lesion-directed therapy with realistic expectations, and, most importantly, a relentless focus on identifying and managing the systemic cardiovascular risk factors—is essential for optimal patient outcomes. Treating the xanthelasma effectively means looking past the eyelids and into the patient’s long-term health.

12. Frequently Asked Questions (FAQs)

Q1: I have xanthelasma but my cholesterol test came back normal. Is this possible?
A: Yes, this is possible in up to half of all cases. It may be due to normal fluctuations in lipid levels, previously elevated lipids that have since normalized, or a strong influence from local tissue factors. However, it could also indicate high levels of Lipoprotein(a) [Lp(a)], which is not always included in a standard lipid panel. Discuss testing for Lp(a) with your doctor.

Q2: Will removing my xanthelasma lower my risk of heart disease?
A: No. Removing the visible lesion does nothing to alter your underlying lipid profile or systemic cardiovascular risk. The treatment is purely cosmetic. The key to reducing heart disease risk is managing the underlying dyslipidemia through lifestyle changes and medication if necessary.

Q3: What is the best treatment for xanthelasma?
A: There is no single “best” treatment for everyone. The optimal choice depends on the size, thickness, and location of your lesions, as well as your skin type and personal preference. Ablative lasers (like CO2) and surgical excision are often considered the most effective for complete removal, but your dermatologist or oculoplastic surgeon can best advise you after an examination.

Q4: Can xanthelasma be prevented?
A: If you have a genetic predisposition, it may not be entirely preventable. However, maintaining a healthy lifestyle—a diet low in saturated and trans fats, regular exercise, maintaining a healthy weight, and not smoking—can help keep your lipid levels in check and may delay the onset or reduce the severity of xanthelasma.

Q5: Are xanthelasma painful or dangerous to my vision?
A: Xanthelasma are almost never painful, itchy, or dangerous to your vision. In extremely rare cases, a very large lesion might cause mechanical drooping of the eyelid (ptosis), which could potentially obscure vision, but this is highly unusual. The primary significance of xanthelasma is its association with systemic health.

13. Additional Resources

• American Academy of Dermatology (AAD): Provides patient-friendly information on skin conditions and a tool to find a board-certified dermatologist. https://www.aad.org/

• American Heart Association (AHA): An excellent resource for understanding cholesterol, cardiovascular disease, and lifestyle management. https://www.heart.org/

• National Institutes of Health (NIH) – National Heart, Lung, and Blood Institute (NHLBI): Provides in-depth, science-based information on blood cholesterol and dyslipidemias. https://www.nhlbi.nih.gov/health-topics/blood-cholesterol

• ICD-10-CM Official Guidelines for Coding and Reporting: For healthcare professionals seeking the most detailed coding instructions. https://www.cms.gov/medicare/coding-billing/icd-10-cm

Date: November 05, 2025
Author: The Medical Writing Team

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.